Amendment 36C25721Q0579 0001.pdf

5. PROJECT NUMBER (if applicable)

CODE7. ADMINISTERED BY

2. AMENDMENT/MODIFICATION NUMBER

CODE

6. ISSUED BY

8. NAME AND ADDRESS OF CONTRACTOR

4. REQUISITION/PURCHASE REQ. NUMBER3. EFFECTIVE DATE

9A. AMENDMENT OF SOLICITATION NUMBER

9B. DATED

PAGE OF PAGES

10A. MODIFICATION OF CONTRACT/ORDER NUMBER

10B. DATED

BPA NO. 1. CONTRACT ID CODE

FACILITY CODECODE

Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:

The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers

E. IMPORTANT:

is extended,

(a) By completing Items 8 and 15, and returning __________ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY is not extended.

12. ACCOUNTING AND APPROPRIATION DATA

(REV. 11/2016)

is required to sign this document and return ___________ copies to the issuing office.is not, A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

15C. DATE SIGNED

B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

D. OTHER

Contractor

16C. DATE SIGNED

14. DESCRIPTION OF AMENDMENT/MODIFICATION

16B. UNITED STATES OF AMERICA

Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

15A. NAME AND TITLE OF SIGNER 16A. NAME AND TITLE OF CONTRACTING OFFICER

15B. CONTRACTOR/OFFEROR

STANDARD FORM 30 PREVIOUS EDITION NOT USABLE

Prescribed by GSA - FAR (48 CFR) 53.243

(Type or print) (Type or print)

(Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

(Number, street, county, State and ZIP Code)

(If other than Item 6)

(Specify type of modification and authority)

(such as changes in paying office, appropriation date, etc.)

(If required)

(SEE ITEM 11)

(SEE ITEM 13)

(X)

CHECK

ONE

13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS,

IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT

(Signature of person authorized to sign) (Signature of Contracting Officer)

1 3

0001 None

Department of Veterans Affairs VISN17 Network Contracting Activity 7400 Merton Minter Blvd. (10N17/90C) San Antonio TX 78229

Department of Veterans Affairs VISN17 Network Contracting Activity 7400 Merton Minter Blvd. (10N17/90C) San Antonio TX 78229

To all Offerors/Bidders

36C25721Q0579

02-18-2021

X

X X

X 1

The purpose of this amendment is to provide responses to questions asked during the question and answer period.

No further questions will be answered concerning this solicitation.

All responses to this solicitation are due by April 30, 2021, 3:00 PM Eastern Time.

Question: What are the components and sample types acceptable for the tests described in the “Test Name” Column of the table below?

Answer: See the “Components” and “Sample type” columns.

Test name Components Sample type Encephalopathy, Autoimmune Evaluation, serum

Encephalopathy, Autoimmnue Evaluation, CSF

Encephalopathy, Interpretation, AChR Ganglionic Neuronal Ab, AMPA-R Ab CBA, Amphiphysin Ab, Anti-Glial Nuclear Ab, Type 1 Anti-Neuronal Nuclear Ab, Type 1 Anti-Neuronal Nuclear Ab, Type 2 Anti-Neuronal Nuclear Ab, Type 3 CASPR2-IgG CBA, CRMP-5-IgG, DPPX Ab IFA, GABA-B-R Ab CBA, GAD65 Ab Assay, GFAP IFA, IgLON5 IFA, LGI1-IgG CBA, mGluR1 Ab IFA, NIF IFA, NMDA-R Ab CBA, N-Type Calcium Channel Ab P/Q-Type Calcium Channel Ab Purkinje Cell Cytoplasmic Ab Type 1 Purkinje Cell Cytoplasmic Ab Type 2 Purkinje Cell Cytoplasmic Ab Type Tr

Reflex testing if necessary AGNA-1 Immunoblot, Alpha Internexin CBA, AMPA-R Ab IF Titer Assay, Amphiphysin Immunoblot, ANNA-1 Immunoblot, ANNA-2 Immunoblot, CRMP-5-IgG Western Blot, DPPX Ab CBA, DPPX Ab IFA Titer, GABA-B-R Ab IF Titer Assay, GFAP CBA, GFAP IFA Titer, IgLON5 CBA, IgLON5 IFA Titer, mGluR1 Ab CBA, mGluR1 Ab IFA Titer, NIF Heavy Chain CBA, NIF IFA Titer, NIF Light Chain CBA, NMDA-R Ab IF Titer Assay, PCA-1 Immunoblot, PCA-Tr Immunoblot

Serum and CSF

Erythrocytosis Evaluation Erythrocytosis Interpretation:

Hb Variant, A2 and F Quantitation,B HPLC Hb Variant, Whole blood

Oxygen Dissociation P50 P50 Shipping Control Vial Hb Variant by Mass Spec

Reflex testing if necessary Sickle Solubility, Hereditary Erythrocytosis Mut, Isoelectric Focusing, Hb Stability, Hb F Distribution, Alpha-Globin Gene Analysis Alpha Globin Gene Sequencing, Beta Globin Gene Sequencing, Beta Globin Cluster Locus Del/Dup, Gamma Globin Full Gene Sequencing BPGM Full Gene Sequencing VHL Gene Erythrocytosis Mutations Erythrocytosis Summary Interpretation

Fungitell, Bronchalveolar lavage Beta D Glucan BAL IgG Subtypes, Tissue Immunofluorescence Ab stain Renal Biospy tissue RBC Membrane Evaluation Osmotic Fragility

Shipping Control Vial Spherocytosis Interpretation Band 3 Fluorescence Staining, RBC Peripheral Blood Smear Review

Control specimen EDTA Whole blood EDTA Whole Blood Slide

Schistosoma Exam, Random Urine Microscopic evaluation Urine